Casual Friday Series

Immune Boost? When and why...Part 2


A Biogenetix Clinical Presentation
BIOGENETIX.COM



Disclaimer

- Information in this presentation is not intended, in itself, to diagnose, treat, reverse, cure, or prevent any disease. While this presentation is based on medical literature, findings, and text, The following statements have not been evaluated by the FDA.
- The information provided in this presentation is for your consideration only as a practicing health care provider. Ultimately you are responsible for exercising professional judgment in the care of your own patients.





Lifestyle + Genetics = Chronic Health IMPROVEMENT



Back in the Day: TH1 vs TH2

Intracellular

TH1


- Multiple sclerosis
- Hashimoto's
- Grave's
- Rheumatoid arthritis
- Lyme arthritis
- Psoriatic arthritis
- Contact dermatitis
- Type 1/1.5 diabetes
- Erythema nodosum
- Frequent spontaneous abortion
- Psoriasis
- Primary biliary cirrhosis
- Pulmonary sarcoidosis
- Crohn's disease
- Inflammatory bowel disease
- Etc.


Extracellular


TH2

- Asthma
- A topic dermatitis
- Conjunctivitis
- Hyper eosinophilia
- Allergies
- Normal pregnancy
- Systemic lupus erythematosus
- Sclera derma
- Etc.





















What happens when this TH1 on-ramp is fully committed?





Front Cell Infect Microbiol. 2021; 11: 624483.

Published online 2021 Feb 26. doi: 10.3389/fcimb.2021.624483

PMCID: PMC7952877

PMID: 33718270

T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression

Francisco Javier Gil-Etavo. 1 Patricia Suàrez-Fernández. 2 Oscar Cabrera-Marante. 1 Daniel Arrovo. 1 Sara Garcinuño,

² Laur Rague

Auth

The immune response type organized against viral infection is determinant in the prognosis of some infections. This work has aimed to study Th polarization in acute COVID-19 and its possible association with the outcome through an observational prospective study. Fifty-eight COVID-19 patients were recruited in the Medicine Department of the hospital "12 de Octubre," 55 patients remaining after losses to follow-up. Four groups were established according to maximum degree of disease progression. T-helper cell percentages and phenotypes, analyzed by flow cytometer, and serum cytokines levels, analyzed by Luminex, were evaluated when the microbiological diagnosis (acute phase) of the disease was obtained. Our study found a significant reduction of %Th1 and %Th17 cells with higher activated %Th2 cells in the COVID-19 patients compared with reference population. A higher percent of senescent Th2 cells was found in the patients who died than in those who survived. Senescent Th2 cell percentage was an independent risk factor for death (OR: 13.88) accompanied by the numbers of total lymphocytes (OR: 0.15) with an AUC of 0.879. COVID-19 patients showed a profile of pro-inflammatory serum cytokines compared to controls, with higher levels of IL-2, IL-6, IL-15, and IP-10. IL-10 and IL-13 were also elevated in patients compared to controls. Patients who did not survive presented significantly higher levels of IL-15 than those who recovered. No significant differences were observed according to disease progression groups. The study has shown that increased levels of IL-15 and a high Th2 response are associated with a fatal outcome of the disease.





Cellular Senescence


Cellular senescence is defined as irreversible cell cycle arrest driven by a variety of mechanisms, including telomere shortening, other forms of genotoxic stress, or mitogens or inflammatory cytokines, that culminate in the activation of the p53 tumor suppressor and/or the cyclindependent kinase inhibitor p16.

https://www.sciencedirect.com/topics/medicine-and-dentistry/cellular-senescence









Case #1 53 YO Female

CBC With Differential/Platelet				
WBC	4.9		x10E3/uL	3.4-10.8
RBC	5.21		x10E6/uL	3.77-5.28
Hemoglobin	14.8		g/dL	11.1-15.9
Hematocrit	43.0		%	34.0-46.6
MCV	83		fL	79-97
MCH	28.4		pg	26.6-33.0
MCHC	34.4		g/dL	31.5-35.7
RDW	13.1		%	11.7-15.4
Platelets	376		x10E3/uL	150-450
Neutrophils	48		8	Not Estab.
Lymphs	41		8	Not Estab.
Monocytes	7		8	Not Estab.
Eos	3		8	Not Estab.
Basos	1		8	Not Estab.
Neutrophils (Absolute)	2.4		x10E3/uL	1.4-7.0
Lymphs (Absolute)	2.0		x10E3/uL	0.7-3.1
Monocytes (Absolute)	0.3		x10E3/uL	0.1-0.9
Eos (Absolute)	0.1		x10E3/uL	0.0-0.4
Baso (Absolute)	0.0		x10E3/uL	0.0-0.2
Immature Granulocytes	0		૪	Not Estab.
Immature Grans (Abs)	0.0		x10E3/uL	0.0-0.1
Lipids				
Cholesterol, Total	223	High	mg/dL	100-199
Triglycerides	81		mg/dL	0-149
HDL Cholesterol	73		mg/dL	>39
VLDL Cholesterol Cal	14		mg/dL	5-40
LDL Chol Calc (NIH)	136	High	mg/dL	0-99
T. Chol/HDL Ratio	3.1		ratio	0.0-4.4
Please Note:				



Case #1 53 YO Female

Hgb Alc with eAG Estimation

Hemoglobin Alc 10.4 High % 4.8-5.6

Please Note:

Prediabetes: 5.7 - 6.4

Diabetes: >6.4

Glycemic control for adults with diabetes: <7.0


Estim. Avg Glu (eAG) 252 mg/dL

Glucose	263	High	mg/dL	65-99
BUN	5	Low	mg/dL	6-24
Creatinine	0.63		mg/dL	0.57-1.00
eGFR If NonAfricn Am	103		mL/min/1.73	>59



Case #1 53 YO Female

Aspergillus





Case # 49 YO Female

CBC, Platelet Ct, and Diff 01			
WBC ⁰¹	6.3	x10E3/uL	3.4-10.8
RBC 01	4.23	x10E6/uL	3.77-5.28
Hemoglobin ⁰1	12.0	g/dL	11.1-15.9
Hematocrit ⁰¹	38.1	%	34.0-46.6
MCV 01	90	fL	79-97
MCH 01	28.4	pg	26.6-33.0
MCHC 01	31.5	g/dL	31.5-35.7
RDW 01	14.9	%	11.7-15.4
Platelets ⁰¹	312	x10E3/uL	150-450
Neutrophils 01	46	%	Not Estab.
ymphs ⁰¹	45	%	Not Estab
Monocytes 01	7	%	Not Estab.
Eos ⁰¹	1	%	Not Estab.

Homocyst(e)ine 01	8.4	umol/L	0.0-14.5
TSH 01	2.870	uIU/mL	0.450-4.500
Thyroxine (T4) 01	7.0	ug/dL	4.5-12.0
T3 Uptake ⁰¹	25	%	24-39




Case # 49 YO Female


Free Thyroxine Index	1.8		1.2-4.9
Triiodothyronine (T3) 01	107	ng/dL	71-180
Triiodothyronine (T3), Free ⁰¹	2.7	pg/mL	2.0-4.4
Reverse T3, Serum A, 02	17.2	ng/dL	9.2-24.1
T4,Free(Direct) 01	1.12	ng/dL	0.82-1.77
Thyroid Peroxidase (TPO) Ab 01	<9	IU/mL	0-34
Thyroglobulin Antibody 01	<1.0	IU/mL	0.0-0.9

Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval
Chemistries 01					1600 LUVE 13
Glucose ⁰¹	90			mg/dL	65-99
▲ Hemoglobin A1c 01	5.9	High		%	4.8-5.6
Please Note: 01					
X					






Protocols




Immune Support








Immune Support








Biogenetix: 833-525-0001



zeb@biogenetix.com



kim@biogenetix.com

